Technical Analysis for IMUX - Immunic, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| MACD Bullish Signal Line Cross | Bullish | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | -0.90% | |
| Oversold Stochastic | Weakness | -0.90% | |
| Wide Bands | Range Expansion | 2.80% | |
| Oversold Stochastic | Weakness | 2.80% | |
| Boomer Sell Setup | Bearish Swing Setup | 4.76% | |
| NR7 | Range Contraction | 4.76% | |
| Narrow Range Bar | Range Contraction | 4.76% | |
| Wide Bands | Range Expansion | 4.76% |
| Alert | Time |
|---|---|
| Possible Inside Day | about 13 hours ago |
| Down 3% | about 17 hours ago |
| Down 2 % | about 17 hours ago |
| 10 DMA Resistance | about 17 hours ago |
| Down 1% | about 17 hours ago |
Get a Trading Sidekick!
- Earnings date: 08/01/2024
Immunic, Inc. Description
Immunic, Inc. (Nasdaq:IMUX) is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORĪ³t; and IMU-856 targets the restoration of the intestinal barrier function. Immunic's lead development program, IMU-838, is in phase 2 clinical development for ulcerative colitis and relapsing-remitting multiple sclerosis, with an additional phase 2 trial in Crohn's disease planned for 2019. An investigator-sponsored proof-of-concept clinical trial for IMU-838 in primary sclerosing cholangitis is planned to start at the Mayo Clinic.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Immunology Immunotherapy Autoimmune Disease Clinical Development Multiple Sclerosis Psoriasis Ulcerative Colitis Metabolism Ulcer Abdominal Pain Colitis Crohn's Disease Molecule Product Mayo Clinic Primary Sclerosing Cholangitis Inflammatory And Autoimmune Diseases
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2.11 |
| 52 Week Low | 0.97 |
| Average Volume | 935,531 |
| 200-Day Moving Average | 1.33 |
| 50-Day Moving Average | 1.40 |
| 20-Day Moving Average | 1.17 |
| 10-Day Moving Average | 1.11 |
| Average True Range | 0.09 |
| RSI (14) | 36.31 |
| ADX | 30.76 |
| +DI | 11.34 |
| -DI | 20.29 |
| Chandelier Exit (Long, 3 ATRs) | 1.21 |
| Chandelier Exit (Short, 3 ATRs) | 1.29 |
| Upper Bollinger Bands | 1.32 |
| Lower Bollinger Band | 1.01 |
| Percent B (%b) | 0.29 |
| BandWidth | 26.81 |
| MACD Line | -0.09 |
| MACD Signal Line | -0.09 |
| MACD Histogram | 0.0029 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.19 | ||||
| Resistance 3 (R3) | 1.19 | 1.15 | 1.18 | ||
| Resistance 2 (R2) | 1.15 | 1.13 | 1.16 | 1.17 | |
| Resistance 1 (R1) | 1.13 | 1.12 | 1.11 | 1.13 | 1.16 |
| Pivot Point | 1.09 | 1.09 | 1.09 | 1.10 | 1.09 |
| Support 1 (S1) | 1.07 | 1.07 | 1.05 | 1.07 | 1.04 |
| Support 2 (S2) | 1.03 | 1.06 | 1.04 | 1.03 | |
| Support 3 (S3) | 1.01 | 1.03 | 1.03 | ||
| Support 4 (S4) | 1.01 |
